Circadian pharmacokinetics of methotrexate.
Six patients with intermediate- and high-grade non-Hodgkin's lymphoma were treated with 400 mg/m2 i.v. methotrexate (MTX) at 0600 and 1800 hours. Despite evidence of circadian rhythms in renal function, the pharmacokinetics of total and free serum MTX showed no significant difference between these two times. The marked two-fold circadian variation in MTX pharmacokinetics previously reported in rats was not observed in these patients.
Robinson
B A
BA
Department of Clinical Oncology, Christchurch Hospital, New Zealand.
Begg
E J
EJ
Colls
B M
BM
Jeffery
G M
GM
Sharman
J R
JR
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002940:Circadian Rhythm / Q000502:physiology*; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000493:pharmacokinetics*; D008875:Middle Aged
D008727:Methotrexate